GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Nanopore Technologies PLC (OTCPK:OXFYY) » Definitions » Loans Receivable

OXFYY (Oxford Nanopore Technologies) Loans Receivable : $0.0 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Oxford Nanopore Technologies Loans Receivable?

Oxford Nanopore Technologies's Loans Receivable for the quarter that ended in Dec. 2024 was $0.0 Mil.


Oxford Nanopore Technologies Loans Receivable Historical Data

The historical data trend for Oxford Nanopore Technologies's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Nanopore Technologies Loans Receivable Chart

Oxford Nanopore Technologies Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial - - - - -

Oxford Nanopore Technologies Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Oxford Nanopore Technologies Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Oxford Nanopore Technologies Loans Receivable Related Terms

Thank you for viewing the detailed overview of Oxford Nanopore Technologies's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford Nanopore Technologies Business Description

Traded in Other Exchanges
Address
Edmund Halley Road, Gosling Building, Oxford Science Park, Oxford, Oxfordshire, GBR, OX4 4DQ
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing.